- Home
- KRRO vs ENTA Comparison
KRRO vs ENTA Comparison
Compare KRRO & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRRO
- ENTA
- Stock Information
- Founded
- KRRO 2014
- ENTA 1995
- Country
- KRRO United States
- ENTA United States
- Employees
- KRRO N/A
- ENTA N/A
- Industry
- KRRO Biotechnology: Pharmaceutical Preparations
- ENTA Biotechnology: Pharmaceutical Preparations
- Sector
- KRRO Health Care
- ENTA Health Care
- Exchange
- KRRO Nasdaq
- ENTA Nasdaq
- Market Cap
- KRRO 358.3M
- ENTA 316.2M
- IPO Year
- KRRO 2019
- ENTA 2013
- Fundamental
- Price
- KRRO $34.30
- ENTA $10.96
- Analyst Decision
- KRRO Strong Buy
- ENTA Strong Buy
- Analyst Count
- KRRO 8
- ENTA 5
- Target Price
- KRRO $96.25
- ENTA $21.00
- AVG Volume (30 Days)
- KRRO 194.0K
- ENTA 464.8K
- Earning Date
- KRRO 11-12-2025
- ENTA 11-17-2025
- Dividend Yield
- KRRO N/A
- ENTA N/A
- EPS Growth
- KRRO N/A
- ENTA N/A
- EPS
- KRRO N/A
- ENTA N/A
- Revenue
- KRRO $6,281,000.00
- ENTA $64,806,000.00
- Revenue This Year
- KRRO $116.91
- ENTA $0.07
- Revenue Next Year
- KRRO N/A
- ENTA N/A
- P/E Ratio
- KRRO N/A
- ENTA N/A
- Revenue Growth
- KRRO N/A
- ENTA N/A
- 52 Week Low
- KRRO $10.29
- ENTA $4.09
- 52 Week High
- KRRO $76.79
- ENTA $15.34
- Technical
- Relative Strength Index (RSI)
- KRRO 42.32
- ENTA 54.80
- Support Level
- KRRO $31.17
- ENTA $10.44
- Resistance Level
- KRRO $42.70
- ENTA $11.34
- Average True Range (ATR)
- KRRO 3.80
- ENTA 0.63
- MACD
- KRRO -1.37
- ENTA -0.07
- Stochastic Oscillator
- KRRO 20.10
- ENTA 62.00
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.